Core Viewpoint - Quantum BioPharma Ltd. is actively participating in two upcoming conferences to engage with institutional investors and showcase its innovative biopharmaceutical solutions [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis, currently in preclinical development [4]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which markets the unbuzzd™ product, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty rate will decrease to 3% [4]. Conference Participation - Jason Sawyer, the Head of Finance and M&A, will represent Quantum BioPharma at the Sidoti Micro-Cap Conference on May 21, 2025, and the A.G.P. Virtual Healthcare Conference on May 22, 2025 [2][3]. - At the Sidoti Micro-Cap Conference, Sawyer will host one-on-one meetings with institutional investors and deliver a webcast presentation [2][3].

Core Viewpoint - Quantum BioPharma Ltd. has completed dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302, aimed at treating Multiple Sclerosis, which is a significant step towards submitting an IND application to the US FDA [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, including Multiple Sclerosis [3]. - The company is advancing its lead compound, Lucid-MS, which is a patented new chemical entity designed to prevent and reverse myelin degradation, a key mechanism in Multiple Sclerosis [3]. Development Progress - The completion of toxicity studies for Lucid-21-302 brings the company closer to initiating a Phase 2 trial for Multiple Sclerosis [2]. - The company plans to submit the IND application for Lucid-21-302 before the end of the year [2]. Strategic Investments - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition, which is involved in the OTC version of its product unbuzzd™. The agreement includes a 7% royalty on sales until total payments reach $250 million, after which the royalty will drop to 3% [3]. - The company maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3].

Company Overview - Quantum BioPharma Ltd. is hosting a Business Update Conference Call on May 6, 2025, at 04:30 PM ET, led by its Founder and CEO, Zeeshan Saeed, and Head of Finance and M&A, Jason Sawyer [1][5]. Forward-Looking Statements - The conference call may include forward-looking statements that represent the company's current judgment on future events, which are subject to risks and uncertainties that could lead to actual results differing materially [2][4]. - Participants are cautioned not to place undue reliance on these forward-looking statements, as they reflect opinions only as of the date of the presentation [3].

Core Viewpoint - Quantum BioPharma Ltd. has filed an amended complaint alleging market manipulation by several banks, seeking damages exceeding $700 million USD due to the alleged manipulation of its stock price through "spoofing" techniques from January 2020 to August 2024 [1][2][3]. Group 1: Legal Proceedings - The amended complaint was filed on May 1, 2025, in response to a Motion to Dismiss from the banks [1]. - The lawsuit claims that CIBC World Markets and RBC Dominion Securities, among others, violated the Securities Exchange Act of 1934 [1][2]. - The law firms Christian Attar and Freedman Normand Friedland LLP are representing the company on a contingency basis, alleviating financial pressure for legal costs [2]. Group 2: Allegations of Market Manipulation - The complaint alleges that the defendants engaged in "spoofing" techniques that artificially depressed Quantum BioPharma's stock price [2]. - The company asserts that the stock was trading over $460 USD per share in January 2020, with a market capitalization nearing $1 billion USD [3]. - Quantum BioPharma believes that additional banks and brokers may also be involved in the alleged manipulation but will not disclose their names until more evidence is gathered [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [7]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [8]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which includes a royalty agreement on sales from its product unbuzzd™ [8].

Core Viewpoint - Quantum BioPharma Ltd. is set to host a Business Update Conference Call on May 6, 2025, to discuss its year-end financial results, regulatory initiatives, commercial-readiness activities, and anticipated milestones [1][2]. Group 1: Conference Call Details - The conference call will be led by CEO Zeeshan Saeed and Head of Finance and M&A Jason Sawyer, followed by a Q&A session [2]. - The call is scheduled for May 6, 2025, at 4:30 p.m. Eastern time, with dial-in and webcast access provided [2]. - A telephone replay will be available approximately three hours after the call and will run until August 6, 2025 [2]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [3]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation associated with multiple sclerosis, showing promise in preclinical models [3]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition, which markets the unbuzzd™ product, and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will decrease to 3% [3].

Core Viewpoint - Quantum BioPharma Ltd. has appointed Kevin Malone as an advisor to the Board of Directors, leveraging his extensive experience in wealth management and stock trading, particularly in combating market manipulation [1][5]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, including multiple sclerosis (MS) [7]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation, a key factor in MS, and is currently in preclinical development [7]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition Corp., which markets the product unbuzzd™, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty rate will drop to 3% [7]. Kevin Malone's Background - Kevin Malone has over 40 years of experience in wealth management and launched Malone Wealth in 2021, focusing on pattern recognition and data research [2]. - His investment philosophy emphasizes rigorous research, disciplined risk management, and a long-term approach to maximize returns while minimizing risk [3]. - Malone is committed to fighting market corruption and has initiated a charitable fund aimed at improving financial literacy in the U.S. public education system [4]. Strategic Importance of Malone's Appointment - The CEO of Quantum BioPharma, Zeeshan Saeed, expressed enthusiasm about Malone's expertise, particularly in naked short squeeze strategies, which will enhance the company's efforts against market manipulation [5]. - Malone's personal experiences with market corruption, including the GameStop incident in 2021, have motivated him to become a fiduciary dedicated to combating such practices [6].

Core Viewpoint - Quantum BioPharma Ltd. has successfully dismissed a reconsideration motion by Dr. Raza Bokhari, affirming the company's position in a legal dispute regarding his termination as CEO [1][2]. Legal Proceedings - Dr. Raza Bokhari's claim of wrongful dismissal was dismissed by Arbitrator Cunningham, resulting in Quantum BioPharma being awarded approximately CAD $2.81 million in arbitration costs plus interest [2]. - The Court of Appeal awarded an additional CAD $180,000 in costs related to Dr. Bokhari's failed motion for leave to appeal [2]. - Quantum BioPharma has initiated a Petition to Confirm Arbitration Award in the U.S. District Court to collect the awarded amounts from Dr. Bokhari, which includes various monetary judgments totaling USD $147,301.04 and CAD $2,814,229.15, among others [3]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [4]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition Corp., which markets the product UNBUZZD™, and is entitled to a 7% royalty on sales until reaching CAD $250 million, after which the royalty rate will decrease to 3% [4].

Core Viewpoint - Quantum BioPharma's licensee, Celly Nutrition, has formed a significant partnership with the Asian American Trade Associations Council (AATAC) to enhance the retail distribution of its product unbuzzd™, which aids in alcohol metabolism and reduces hangover symptoms [1][3]. Group 1: Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders [8]. - Celly Nutrition is a public issuer specializing in wellness and recovery supplements, with its product unbuzzd™ designed to help consumers process alcohol more effectively and improve mental clarity [5][9]. Group 2: Partnership Details - The partnership with AATAC aims to expand unbuzzd™'s retail presence across the United States, leveraging AATAC's network of over 50,000 members and 80,000 locations, including major convenience store brands [2][3]. - AATAC has a history of successfully launching innovative products in the retail space, indicating a strong potential for unbuzzd™ to achieve significant sales [2][4]. Group 3: Product Information - unbuzzd™ is scientifically validated through clinical trials to accelerate alcohol metabolism, reduce blood alcohol concentration, and alleviate hangover symptoms [6]. - The product is available in various packaging options, including 3-pack, 8-pack, and 18-pack formats, and is sold through platforms like Amazon and the official website [6].

Core Viewpoint - Quantum BioPharma Ltd. announced the launch of its anti-hangover beverage, unbuzzd, in Puerto Rico through its licensee Celly Nutrition and distribution partner FUSION Distribution Group, aiming to expand its market presence in the Caribbean region [1][5]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative solutions for neurodegenerative and metabolic disorders, including alcohol misuse [11]. - Celly Nutrition Corporation is a public issuer specializing in wellness and recovery supplements, with unbuzzd developed by a team in pharmacology and medicine [7]. - FUSION Distribution Group is a leading distributor of health-conscious food and beverages in Puerto Rico and the Caribbean, with a strong network including major retailers [4][6]. Product Details - unbuzzd is designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, supported by a double-blind placebo-controlled study [3][8]. - The product is available in convenient "On-the-Go Powder Stick Packs" and can be purchased in various pack sizes [9]. Distribution Strategy - FUSION will distribute unbuzzd across various retail channels in Puerto Rico, including grocery stores, pharmacies, and hospitality venues, aiming for widespread consumer accessibility [5][4]. - The partnership with FUSION is seen as a significant milestone for Celly Nutrition in expanding unbuzzd's retail availability [5]. Financial Arrangement - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition and will receive a 7% royalty on unbuzzd sales until reaching $250 million, after which the royalty will decrease to 3% [11].

Core Viewpoint - Quantum BioPharma Ltd. has entered into a joint clinical study with Massachusetts General Hospital to validate a novel PET imaging technique for monitoring myelin integrity in multiple sclerosis patients [1][2]. Group 1: Clinical Study Details - The clinical study is titled "Preliminary Evaluation of [18F]3F4AP PET as a potential tool to monitor non-immunomodulatory drugs in multiple sclerosis" and is led by Dr. Pedro Brugarolas from MGH [2]. - The study will involve serial [18F]3F4AP PET scans alongside MRI scans in patients with both progressive and relapsing-remitting forms of MS [2]. - Previous studies indicated that [18F]3F4AP is highly sensitive to demyelinated lesions, suggesting its potential as a biomarker for monitoring demyelination changes in response to treatments [2]. Group 2: Company Insights - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative disorders, with its lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation [4]. - The company retains a 25.71% ownership stake in Celly Nutrition, which is involved in the development of the UNBUZZD™ product, and will receive a 7% royalty on sales until total payments reach $250 million, after which the royalty will drop to 3% [4]. - The collaboration with MGH is seen as relevant to the Lucid-MS clinical development program, which aims to protect the myelin sheath in MS [3].